• US therapeutic: $561M (+5% QoQ, +19% YoY) • US cosmetic: $397M (+12% QoQ*, +31% YoY) -- US total: $958M (59% therapeutic; 41% cosmetic) was 74% of worldwide total
• Ex-US therapeutic: $110M (flat QoQ, +14% YoY) • Ex-US cosmetic: $229M (+21% QoQ*, +27% YoY) -- Ex-US total: $339M (32% therapeutic; 68% cosmetic) was 26% of worldwide total
*Botox cosmetic sales are seasonally stronger during the second and fourth calendar quarters than the first and third calendar quarters.